# Scorpion Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/scorpion-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.scorpiontx.com
- Total disclosed funding: $380M
- Latest round: Series C (Jul 1, 2024)
- Investors on record: 20

## About

Scorpion Therapeutics, Inc., based in the US, is a biotechnology company focused on precision oncology, developing targeted therapies for patients with cancer.Founded in 2020 and headquartered in Boston, US, Scorpion Therapeutics specializes in precision oncology, developing targeted therapies for cancer. The company has engaged in 4 deals, with the most recent being a TRADE SALE on January 13, 2025, where Eli Lilly and Company Limited acquired Scorpion for USD 2.5 billion. The CEO, Axel Hoos, leads the company, which has not undergone any notable pivots since its inception.Scorpion Therapeutics specializes in precision oncology, primarily focusing on the development of transformational targeted therapies for patients with cancer. Its core product offering includes STX-478, a mutant-selective PI3Ka inhibitor currently in a Phase 1/2 clinical trial for treating breast cancer and other advanced solid tumors. STX-478 is designed to selectively inhibit the PI3Ka pathway in cancerous cells, addressing the unmet therapeutic needs of patients with hormone-positive breast cancers. Scorpion's pipeline also includes several other internally discovered clinical product candidates and discovery-stage programs targeting previously undruggable cancer pathways. The company primarily serves oncology patients in the US, with aspirations for broader geographic reach as their products advance through clinical development.Scorpion Therapeutics generates revenue through strategic partnerships and licensing agreements related to its innovative oncology therapies. The financial structure includes milestone payments tied to regulatory and clinical development benchmarks, along with potential royalties from future product sales. STX-478, as the flagship product, is expected to attract interest from healthcare providers and pharmaceutical partners due to its novel mechanism. Revenue streams are supported by collaboration with Eli Lilly and Company, which has agreed to acquire Scorpion's PI3Ka inhibitor program, allowing for additional funding based on the successful progression of STX-478 and its integration into Lilly’s oncology pipeline.Scorpion Therapeutics plans to leverage its recent acquisition by Eli Lilly and Company to expand its drug discovery efforts and enhance its oncology product pipeline. They are focused on advancing STX-478 and other pipeline candidates, with the goal of entering new markets and geographic regions, particularly in North America and Europe, by 2026. The acquisition is aimed at utilizing Eli Lilly's resources to support these initiatives, reinforcing Scorpion's commitment to developing innovative oncology treatments.

## Funding rounds

- Series C, Jul 1, 2024, $126M — Abingworth, Atlas Venture, Frazier Healthcare Partners, Lightspeed Venture Partners, OrbiMed Advisors, Invus [DUP], Wellington Management, Nextech, Fidelity Investments, Willett Advisors, Surveyor Capital, Omega Funds, Casdin Capital, EcoR1 Capital, Vida Ventures, Logos Capital, Woodline Partners, Boxer Capital
- Series B, Nov 20, 2020, $147M — Abingworth, Atlas Venture, OrbiMed Advisors, Invus [DUP], Wellington Management, Nextech, Omega Funds, Casdin Capital, EcoR1 Capital, Boxer Capital, Vida Ventures, Janus Henderson Investors, Surveyor Capital, Woodline Partners, Logos Capital
- Series A, Oct 26, 2020, $107M — Abingworth, Atlas Venture, Omega Funds, Mass General Brigham Ventures, Vida Ventures

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A, Series B, Series C
- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B, Series C
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A, Series B, Series C
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series A
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series A, Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C
- Invus [DUP] — Series B, Series C
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series B, Series C
- Nextech (https://capitalatlas.ai/funds/nextech) — Series B, Series C
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B, Series C
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B, Series C
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series B, Series C
- Janus Henderson Investors — Series B
- Surveyor Capital — Series B, Series C
- Woodline Partners — Series B, Series C
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B, Series C
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series C
- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C
- Willett Advisors — Series C